JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 18, 2006; DOI: 10.1124/jpet.106.102129


0022-3565/06/3181-117-123$20.00
JPET 318:117-123, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.102129v1
318/1/117    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DiFabio, J. M.
Right arrow Articles by Parker, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DiFabio, J. M.
Right arrow Articles by Parker, J. D.

TOXICOLOGY

Nitroglycerin Attenuates Human Endothelial Progenitor Cell Differentiation, Function, and Survival

Jonathan M. DiFabio, George R. Thomas, Liana Zucco, Michael A. Kuliszewski, Brian M. Bennett, Michael J. Kutryk, and John D. Parker

Division of Cardiology, Department of Medicine, Mount Sinai and University Health Network Hospitals, and Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada (J.M.D., G.R.T., J.D.P.); Division of Cardiology, Terrence Donnelly Heart Centre, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada (L.Z., M.A.K., M.J.K.); and Department of Pharmacology and Toxicology, Faculty of Health Sciences, Queen's University at Kingston, Kingston, Ontario, Canada (B.M.B.)

Endothelial progenitor cells (EPCs) participate in angiogenesis and the response to chronic ischemia. Risk factors and cardiovascular disease attenuate EPC number, function, and survival. Continuous therapy with nitroglycerin (glyceryl trinitrate; GTN) is associated with increased vascular oxidative stress, leading to nitrate tolerance and endothelial dysfunction. Thus, GTN therapy may also affect EPCs. The purpose of this study was to determine whether continuous exposure to GTN in vivo or during ex vivo expansion affects the circulating number and functional characteristics of human EPCs. To determine the effects of continuous in vivo GTN exposure, EPCs isolated from 28 healthy males before and after receiving 0.6 mg/h GTN (n = 17) or no treatment (n = 11) for 1 week were expanded for 6 days and compared. To determine the effects of continuous ex vivo GTN exposure, EPCs isolated before randomization were expanded for 6 days in medium supplemented with 100 nM, 300 nM, or 1 µM GTN. EPCs expanded without GTN served as controls (n = 10). In vivo, GTN exposure significantly increased the percentage of circulating cells expressing the EPC marker CD34 and increased the susceptibility of expanded EPCs to apoptosis but had no impact on the phenotypic differentiation or migration of EPCs. Ex vivo, GTN exposure increased apoptosis while decreasing phenotypic differentiation, migration, and mitochondrial dehydrogenase activity of EPCs, compared with EPCs expanded in the absence of GTN. Taken together, these results suggest that continuous GTN therapy might impair EPC-mediated processes, an effect that could be detrimental in the setting of ischemic cardiovascular disease.


Received February 7, 2006; accepted April 17, 2006.

Address correspondence to: Dr. John D. Parker, Mount Sinai Hospital, 600 University Ave., Suite 1609, Toronto, ON, Canada M5G 1X5. E-mail: jdp{at}ca.inter.net




This article has been cited by other articles:


Home page
Eur Heart JHome page
A. M. Leone, M. Valgimigli, M. B. Giannico, V. Zaccone, M. Perfetti, D. D'Amario, A. G. Rebuzzi, and F. Crea
From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells
Eur. Heart J., April 2, 2009; 30(8): 890 - 899.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G.-P. Diller, S. van Eijl, D. O. Okonko, L. S. Howard, O. Ali, T. Thum, S. J. Wort, E. Bedard, J. S. R. Gibbs, J. Bauersachs, et al.
Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension
Circulation, June 10, 2008; 117(23): 3020 - 3030.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Thum, D. Fraccarollo, S. Thum, M. Schultheiss, A. Daiber, P. Wenzel, T. Munzel, G. Ertl, and J. Bauersachs
Differential Effects of Organic Nitrates on Endothelial Progenitor Cells Are Determined by Oxidative Stress
Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 748 - 754.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.